Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)‘s stock had its “neutral” rating reissued by stock analysts at Chardan Capital in a research note issued on Wednesday.

ARWR has been the subject of a number of other research reports. ValuEngine downgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Piper Jaffray Companies reissued a “hold” rating and issued a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Friday, July 28th. Jefferies Group LLC reissued a “hold” rating and issued a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Friday, August 4th. Finally, Cantor Fitzgerald reissued a “hold” rating and issued a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Friday. One equities research analyst has rated the stock with a sell rating and five have given a hold rating to the company’s stock. Arrowhead Pharmaceuticals has an average rating of “Hold” and a consensus target price of $2.00.

Shares of Arrowhead Pharmaceuticals (ARWR) opened at 3.30 on Wednesday. Arrowhead Pharmaceuticals has a 1-year low of $1.20 and a 1-year high of $8.09. The company has a 50 day moving average of $2.41 and a 200 day moving average of $1.88. The firm’s market cap is $246.75 million.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.06. Arrowhead Pharmaceuticals had a negative net margin of 201.84% and a negative return on equity of 46.73%. The company had revenue of $9.34 million during the quarter, compared to the consensus estimate of $5.29 million. On average, equities analysts forecast that Arrowhead Pharmaceuticals will post ($0.42) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Arrowhead Pharmaceuticals, Inc. (ARWR) Receives “Neutral” Rating from Chardan Capital” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/09/16/arrowhead-pharmaceuticals-inc-arwr-receives-neutral-rating-from-chardan-capital.html.

Several hedge funds and other institutional investors have recently bought and sold shares of ARWR. LMR Partners LLP acquired a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter worth about $467,000. Wells Fargo & Company MN lifted its stake in shares of Arrowhead Pharmaceuticals by 144.8% during the 1st quarter. Wells Fargo & Company MN now owns 150,346 shares of the biotechnology company’s stock worth $278,000 after buying an additional 88,933 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 287.9% during the 1st quarter. SG Americas Securities LLC now owns 100,747 shares of the biotechnology company’s stock worth $186,000 after buying an additional 74,776 shares during the last quarter. UBS Asset Management Americas Inc. lifted its stake in shares of Arrowhead Pharmaceuticals by 414.7% during the 1st quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock worth $123,000 after buying an additional 53,500 shares during the last quarter. Finally, Virtu KCG Holdings LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 115.6% during the 2nd quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock worth $161,000 after buying an additional 53,215 shares during the last quarter. Institutional investors own 20.63% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.